According to the analysis of TCGA data set, the frequency of FOXK2 changes in melanoma patients is the highest (>6%), and the mutation rate of breast cancer also ranks in the top six (>4%) (Figure S4a). This evidence concerns the gene FOXK2 and breast carcinoma.